Dr Rebecca Harris
MBioch MSc PhD
Honorary Assistant Professor
of Infectious Disease Modelling and Epidemiology
Rebecca Harris is an Honorary Assistant Professor in TB mathematical modelling and epidemiology. Her research includes the development of mathematical models to assess the epidemiological impact of potential TB vaccines in China, India and sub-Saharan Africa, and the development of a novel low-cost app for spatial mapping of TB in low income settings without address systems to support the design of TB vaccine studies and public health programmes.
Rebecca was awarded an MBioch in Molecular and Cellular Biochemistry and an MSc in Global Health from the University of Oxford in 2008 and 2009, respectively. Subsequently, as Technical Officer in the Global Influenza Programme of the World Health Organization, Rebecca developed influenza management guidelines during the H1N1 pandemic. Prior to joining the School, Rebecca worked as a consultant Epidemiology Manager at GlaxoSmithKline Vaccines, developing epidemiological studies within the RTS,S post-approval plan, disease mapping for NTDs, and as lead epidemiologist for tuberculosis. She joined the School in 2013 as a PhD student, and became Assistant Professor in 2017. In 2020, Rebecca joined Sanofi Pasteur as Head of Vaccine Epidemiology and Modelling for AJPAC (PPH, meningitis and endemic vaccines), and in late 2020 transitioned to the global team as Global Medical Evidence Generation Lead for COVID-19 Vaccines, but remains Honorary Assistant Professor at LSHTM and continues in an active role in TB vaccine modelling research and PhD student supervision at the School.
Rebecca's research focusses on developing mathematical models to estimate the epidemiological impact of promising new TB vaccines in high burden settings, with the goal of informing development of candidates with the greatest potential for future public health impact. Current work includes estimating future epidemiological changes in a range of TB epidemics (e.g. China, India, South Africa) and the potential impact of vaccines in these settings.
To further support epidemiological needs in TB vaccine research, she has developed a spatial mapping app that can be used in clinical trial design and as part of public health programmes: TB ePAL (electronic PArticipant Locator). TB ePAL is a clinic-based tool to collect the location of a patient's place of residence in highly populous settings without addresses. The app is designed to be an easy to implement, low cost, and low resource alternative to GPS collection at the patient's home. The app has been designed and implemented through the MLW research centre in Blantyre, Malawi as part of the Hit TB Hard programme.
Rebecca is part of the TB modelling team, and is involved with the TB Centre, Vaccine Centre and the Centre for the Mathematical Modelling of Infectious Diseases.